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ABSTRACT
QUANTIFYING THE BENEFITS OF THE EXPANDED FOOD AND NUTRITION
EDUCATION PROGRAM (EFNEP) USING BIOMARKERS FOR CHRONIC
DISEASE RISK.
RICHARD ACQUAH-SARPONG
2021
The Expanded Food and Nutrition Education Program (EFNEP) is among the major
nutrition education programs funded by the United States Department of Agriculture
(USDA) with the aim of reducing food insecurity among low-income families. The
program reaches about 70,000 adults and youth of low-income families in the US, District
of Columbia, and six U.S. territories.
Prior studies have used self-reported data, which possesses measurement errors, to estimate
the benefits of the program. This can lead to underestimation or overestimation of results.
To address this limitation, I use clinically measured objective biomarkers, such as body
mass index (BMI), blood sugar level (HbA1C) and blood pressure to estimate the benefits
of EFNEP and compare it to the program costs. Results show that EFNEP benefits
outweigh program costs. However, the use of self-report data underestimates the benefits
of the program.
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CHAPTER 1
1.0 INTRODUCTION
1.1 Background
The Expanded Food and Nutrition Education Program (EFNEP) is one of the
leading nutrition education programs aimed at reducing nutrition insecurity of low-income
families and youth in the United States. Established in 1969 by the US government and
managed by the USDA NIFA, EFNEP is among the earliest nutrition education programs
and remains at the forefront of food and nutrition educational efforts (USDA, 2020). The
program’s main aim is to reduce nutrition insecurity among U.S low-income families and
youth. EFNEP currently operates through the 76 Land-Grant Universities (LGUs) in every
state, the District of Columbia, and six U.S. territories – American Samoa, Guam,
Micronesia, Northern Marianas, Puerto Rico, and the Virgin Islands.
As a community-based nutrition education program, the goal of EFNEP is to
address the health issues of the community as well as to improve the nutritional well-being
of low-income households. EFNEP focuses on four main education areas: improving the
quality of diet and physical activity of participants, proper food resource management, food
safety and food security (USDA, 2020). These goals are accomplished through the
participants’ increased knowledge of the essentials of nutrition, as well as from increased
skills in food selection, purchasing, preparation, production, storage, safety, and sanitation.
The program also seeks to enhance the ability of participants to manage resources relating
to food. The program receives about $70 million in federal funding each year and reaches
approximately 650,000 adults and youth in both rural and urban areas (USDA, 2020).
Researchers such as Lambur et al. (1998), Burney et al., (2002), and Koszewski et al.
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(2011), conclude that EFNEP is an effective use of tax dollars i.e. the benefit of EFNEP in
terms of avoiding or delaying specific chronic diseases, improvements in participants’ food
expenditures, and changes in nutritional behaviors exceed program costs.

1.2 Problem Statement
Over the years, several studies have evaluated the economic efficiency of EFNEP
(Lambur et al., 1998; Burney et al., 2002; and Koszewski et al., 2011). Limitations of the
existing literature, particularly in estimating the direct benefits of EFNEP, motivate this
study. These limitations include the use of self-reported behavioral data, which are dietary
recalls from participants of EFNEP, to determine those who have benefited from the
program. Dietary recalls, which are collected through interviews before their first lesson
and at the last lesson are used to determine those who benefit from the program by
following the behaviors taught in the program. Benefits are measured as the number of
people who have improved their nutrition and health behaviors after graduating from the
program, and hence able to avoid or delay the onset of specific chronic diseases. There are
obvious limitations to self-reporting in that some people may not remember past diets and
physical activity correctly, or they may have difficulty quantifying them accurately (Hagen,
2012). The use of self-reported data and the dietary measurement error it poses can cause
underestimation or overestimation of results (Rosenman et al., 2011). These limitations
likely biased the results of prior EFNEP impact and cost-benefit analyses.
Considering the large amount of federal funding allocated to EFNEP (e.g.
$69,400,680 for 2020) (NIFA,2020), a thorough cost-benefit analysis is needed to advance
the literature by developing a cost-benefit analysis model that provides more accurate
estimates of the net benefits and costs of the program. To address the challenges associated
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with the use of self-reported behavioral data, I make use of objective, quantitative
biological markers (biomarkers) reflective of nutritional intake and indicative of chronic
disease risk (Combs et al., 2013). Biomarkers provide unbiased measurements and are
therefore useful to validate self-report instruments (Hagen, 2012). Examples of biomarkers
include body mass index (BMI), blood pressure (BP) and blood sugar level (HbA1C). This
study will provide other nutrition education programs with a more accurate, easy-to-use
procedure for conducting an economic analysis and give useful information to the
administrators of EFNEP and similar nutrition education programs.

1.3 Objectives
The main objective of this study is to develop and apply a cost-benefit analysis
methodology that provides more accurate estimates of the net benefit of EFNEP by using
objective biomarker data. The specific objectives are to (1) quantify EFNEP benefits using
biomarker data and (2) examine, using biomarkers, if EFNEP behaviors are maintained
one-year-post graduation.
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CHAPTER 2
2.0 LITERATURE REVIEW
2.1 Cost-Benefit Analysis
Cost-benefit analysis (CBA), also referred to as benefit-costs analysis, is a
systematic method to ascertain the value (benefits) of programs or projects against their
costs where both are expressed in monetary terms. Results of CBA are usually expressed
as discounted net benefits (program benefits minus program costs), as a rate of return, or
as a ratio of benefits to costs, (Boardman et al. 2017). CBA provides a framework for
measuring the efficiency of programs and projects. It can be thought of as a situation in
which resources, such as land, labor, and capital, are employed in their highest-valued uses.
(Boardman et al. 2017).
Such a quantitative comparison of program’s benefits to its costs has been widely
applied in the evaluation of health programs including EFNEP within the United States.
Rajgopal, Ruby, Lambur, and Lewis (2002) define the benefits of a program as the
outcomes or consequences that participants or non-participants derive from the program.
The primary positive outcome that participants and others involved in the program derive
directly is referred to as the direct benefit of the program. The secondary outcomes that
program participants and non-participants or society derive indirectly are referred to as its
indirect benefits.
Costs can also be categorized as direct or indirect costs. Budgeted resources are
used directly in the administration of the program while some resources are not budgeted
for but are necessary for operating or running the program. These are referred to as direct
costs and indirect costs, respectively. Indirect costs can be the opportunity costs to the
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individuals for direct involvement in the program. For example, indirect costs include the
lost work hours due to participation in the program (Lambur, Cox, & Ellerbrock, 1998).
2.2 Economic Evaluation of EFNEP
Among the earliest economic evaluations of EFNEP is that of Virginia which
evaluated the cost-benefit of Virginia EFNEP using the CBA methodology (Lambur et al.
1998). Direct benefits were measured as benefits from chronic diseases and conditions that
are diet-related and that would have been delayed or avoided if participants adopted the
behaviors that were taught and measured by EFNEP. The measurement of changes in
behavior was captured from 24-hour dietary recalls reported by participants before and at
the exit of the program. The Virginia methodology calculates direct benefits as the present
value of the medical costs ($ dollars) saved per disease/condition multiplied by the number
of EFNEP graduates who practiced food behaviors associated with avoiding or delaying
the onset of the specific disease/condition (Lambur et al. 1998). Indirect benefits were
measured as benefits that accrued to EFNEP participants due to increased work
productivity. When a person becomes sick or dies, his or her earnings or productivity are
threatened since he or she cannot work anymore. It is beneficial to avoid or delay the onset
of a disease/condition because it has the potential of increasing an individual’s
productivity/earnings significantly. Also, the possibility of avoiding or delaying illness
benefits society indirectly because it increases people’s ability to work. Costs used in the
Virginia methodology were direct administrative costs of the program (Radhika et al.
2002).
Lambur et al. (1998) and Radhika et al. (2002) categorized the disease/conditions
into three types; Type A, B, and C. Type A is the life-threatening diseases/conditions which
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are associated with nutritional behaviors that are expected to be affected positively by
appropriate diet behaviors. These are heart disease, colorectal cancer, hypertension, and
stroke. Type B disease/conditions are non-life-threatening diseases that are also associated
with nutritional behaviors which are expected to be affected positively by appropriate diet
behaviors. These are obesity, type 2 diabetes, osteoporosis, foodborne illness, and
commonly occurring infant diseases. Type C disease/conditions are those whose cost of
treatment is incurred only once such as low birth weight (LBW) in infants. The direct
benefit of type C disease is based on the present value of avoiding the costs of treating an
infant with low birthweight.
After calculating program benefits and costs, Lambur et al. (1998) used three
analytical measures of benefits, namely benefit-cost ratio (BCR), internal rate of return
(IRR), and net present value (NPV) to measure the efficiency of Virginia EFNEP. They
used the 1996 Virginia adult EFNEP self-reported data from the EFNEP Evaluation
Reporting System which included pre and post self-reported data on program participants’
food-related behaviors. The authors concluded that Virginia EFNEP generates a significant
return on investment with a $10.64/$1.00 benefit to cost ratio. Addressing the uncertainty
of whether the results were due to assumptions in their analysis, such as the unavailability
of estimates of incidence rates for some of the disease conditions for low-income
households, they conducted several sensitivity analyses. The result of the sensitivity
analysis was a benefit to cost ratios ranging between $2.66/$1.00 and 17.04/$1.00.
Other studies have looked at the economic evaluation of the EFNEP program in
various states using a similar methodology as that of Virginia evaluation reviewed above
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(Lambur et al. 1998; Radhika et al. 2002). These studies have been summarized in Table
1.
2.3 Behavioral Changes of EFNEP Participants
Burney et al., 2002 analyze whether the benefits of participating in
EFNEP exceed its cost and if these positive behaviors are maintained over a long period.
Using an experimental design in the cost-benefit analysis methodology, a sample size of
384 participants was randomly assigned to one of three different groups to determine
improvements in participants’ food expenditures. Group A are those who received nutrition
education from EFNEP and collected cash receipts for their food purchases; Group B are
those whose food expenditures were estimated from recall; and Group C, the control group,
are those who had qualified for enrollment in the program but had to start their lessons after
groups A and B had graduated from the program. Cash receipts to determine food
expenditures were used to differentiate Group A from Groups B and C. Using the Analysis
of Variance technique, comparing the combined experimental group (A and B) with the
control group, data gathered from food and nutrition intake between entry and exit of the
program showed positive average changes in food and nutrition intake. Statistically,
changes in food and nutrition intake by the experimental group were significantly higher
than those of the control group after participating in EFNEP. Also, there were significantly
higher mean scores of food resources management practices for the experimental group
than the control group. Pairwise comparisons between groups were made and the results
showed that EFNEP participants had the most improvement in their food expenditures and
that they retained their behavior changes from the program over a long period after
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graduation. To compare the benefits, which is the amount of money saved on food
expenditures to the costs, the net present value (NPV) ranged from $147 to $696.
Almost all the studies on the economic evaluation of EFNEP have demonstrated
that the benefits of EFNEP exceed its cost (Amstutz and Dixon, 1969; Arnold and Sober,
2000; Greer and Poling, 2001). But another question of interest and importance is how long
will such positive nutritional behaviors and benefits be sustained? To answer this question,
Koszewski et al. (2011) determined if graduates from either SNAP-Ed or EFNEP in
Nebraska showed changes in their behavior 6 months after completing the program. Data
for the analysis was gathered from EFNEP’s Behavior Checklist Survey and analyzed
using chi-square analysis to determine the effectiveness of SNAP-Ed/EFNEP nutrition
education six months after graduation. The authors found that 25% (n=1,100) of the
graduates from the two programs improved and maintained their behaviors within the entry
and exit of the program, as well as 6 months later. This result was emphasized by Wardlaw
and Baker, (2012) who also conducted a long-term evaluation of EFNEP and SNAP-Ed
using checklists and semi-structured interviews to identify the changes in behavior, food,
and nutrition behaviors as well as other life changes attributed to their involvement in the
program over time. The study sample were previous graduates who were enrolled within
one to four years. The results of their study indicate that following EFNEP participation,
graduates maintained positive food- and nutrition-related behaviors for approximately one
to four years within the period which they were enrolled and they performed these
behaviors more often than non-participants.
The research presented in this subsection indicates positive findings on the
economic efficiency of EFNEP and other related health education programs. Nonetheless,
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there are several limitations associated with the approaches used in these studies such as
their use of self-reported data on dietary intake and behavior changes. This limitation
creates the potential for self-report bias (Rosenman et. al, 2011). Participants may make
more acceptable answers or recall rather than being truthful or may not be able to remember
their food behaviors accurately.
2.4 Self-Report Data and Biomarkers
One challenge in nutrition and health care evaluation is the use of self-reported data
and the measurement error it poses which can cause underestimation or overestimation of
results. Few studies have evaluated self-reported dietary intake data against objective data.
Park et al. (2018) estimated the prevalence of under- and overreporting of dietary intake
by comparing self-reported dietary intakes which were gathered from the automated SelfAdministered 24-hr recall (ASA24s), 4-d food records (4DFRs), and food-frequency
questionnaires (FFQs) against recovery biomarkers. Over a study period of 12 months, 530
men and 545 women, aged 50–74 years were made to complete automated SelfAdministered 24-h recall (ASA24s), 2 unweighted 4-d food records (4DFRs), 2 FFQs, two
24-h urine collections (biomarkers for protein, potassium, and sodium intakes), and 1
administration of doubly labeled water (a biomarker for energy intake). When absolute
intakes of some nutrients were assessed by all self-reported instruments, they were found
to be systematically lower than the absolute intakes of the same nutrients accessed from
recovery biomarkers, though there was underreporting of energy which was greater
compared to the other nutrients. Nutrients accessed were energy, protein, potassium, and
sodium. Comparing estimates of dietary intake from self-reported data with the biomarkers,
there was an underestimation of intake by 15–17% on ASA24s, 18–21% on 4DFRs, and
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29–34% on FFQs. FFQs had the most underreporting compared to ASA24s and 4DFRs
and among obese individuals. Mean protein and sodium densities on ASA24s, 4DFRs, and
FFQs were similar to biomarker values, but potassium density on FFQs was 26–40%
higher, which led to a significant increase in the prevalence of overreporting compared
with absolute potassium intake.
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Table 1: Economic Evaluations of the Expanded Food and Nutrition Education Program.
Citation

Dollahite, Jamie, Donald
Kenkel, and C. Scott
Thompson. "An economic
evaluation of the
expanded food and
nutrition education
program." Journal of
nutrition education and
behavior 40, no. 3 (2008):
134-143.

Objectives

Use economic methodology to
evaluate New York State EFNEP

Methodology
Design: Estimating potential
health benefits using an
epidemiological modeling
approach.
estimates of costeffectiveness are from
behavior change and QALY
weights.
Subjects: 5730 low-income
participants.

Results

Benefit-to-cost ratio of $9.58:$1.00
(sensitivity $1.44-$41.92:$1:00);
Narrow governmental benefit-to-cost
ratio of $0.82:$1.00 (sensitivity
$0.08-$4.33:$1:00).

Setting: 35 counties of New
York State
Hradek, Christine, Helen
H. Jensen, Nicole
Schimerowski Miller, and
Miyoung Oh. "Evaluation
of the Cost and
Effectiveness of Direct
Nutrition Education to
Low-Income Audiences in
Iowa: EFNEP and SNAPEd graduates practicing
Optimal Nutritional
Behaviors (ONB)."
(2017).

Evaluate the costs and benefits of
EFNEP and SNAP-Ed programs
as well as update a study
conducted in Iowa from 1998 to
2000.

Design: Analyze outcomes
and costs based on updated
data collected from the Iowa
EFNEP and FNP program
(updated Virginia
methodology)
Subjects: 947 graduate
participants.
Setting: Iowa State.

Benefit-to-cost ratio of $2.48/$1.00
Less restrictive measures of benefits
lead to
benefit-to-cost ratios between
$1.51/$1.00 - $2.48/$1.00
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Joy, A., Vijay Pradhan,
and George Goldman.
"Cost-benefit analysis
conducted for nutrition
education in
California." California
Agriculture 60, no. 4
(2006): 185-191.
Schuster, Ellen, Zelda L.
Zimmerman, Molly
Engle, Janice Smiley,
Ellen Syversen, and Jill
Murray. "Investing in
Oregon's Expanded Food
and Nutrition Education
Program (EFNEP):
documenting costs and
benefits." Journal of
nutrition education and
behavior 35, no. 4 (2003):
200-206.

Justify and determine
expenditures and ensure
continued funding by
documenting the costeffectiveness of nutrition
education programs

Design: Standard Virginia
methodology.
Subjects:

Benefit-cost ratio of 14.67/1.00.
(Sensitivity 3.67 to 1.00, to 8.34 to
1.00)

Settings: California State

Design: Standard Virginia
methodology.
To estimate a cost-benefit ratio
for Oregon’s EFNEP by applying
the standard CBA model from
Virginia study.

Subjects/Settings: 368 adult
graduates of Oregon State
University’s Extension
Service EFNEP during the
1999-2000 program year.

Benefit-cost ratio of 3.63/1.00
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Rosenman et al. (2011), further demonstrate how to identify self-reported data bias
in response and its covariates by examining how participant demographics affect response
bias before and after program participation. The stochastic frontier model (SFE) by Aigner
et al. (1977) and Meeusen and van den Broeck (1977) was the approach of measuring
response bias and its changes between two time periods. They conclude that the magnitude
of bias and its changes across time are affected by gender and race/ethnicity which is lower
at post-test than at the pre-test.
To address the problem of dietary measurement bias error, efforts have been made
to use biological markers (biomarkers) of nutritional intake (Freedman et al., 2010).
Examples of such biomarkers include weight, body mass index (BMI), blood pressure (BP)
and blood sugar level (A1C). Information on physiological or biological responses to
dietary behavior can provide information on interindividual differences in response to diet
and nutrition revealed by such measurements and be useful to monitor responses to
interventions (Hagen, 2012). Biomarkers provide almost unbiased measurements and are
therefore useful to validate self-report instruments.
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CHAPTER 3
3.0 DATA AND METHODOLOGY
3.1 Participants
EFNEP participants are primarily families with income below the poverty line (USDA,
n.d.). Approximately 70% of EFNEP participants are indicated to be of minority status
(USDA n.d.). The program focuses on minority and low-income groups given their
disproportionate risk for chronic diseases and poor health (USDA n.d.). This study’s
population was composed of 1,507 graduates of EFNEP in both states in 2016-2017, of
which 725 were in Washington and 782 were in Colorado. EFNEP graduates are
participants who completed all their lessons as well as both the entry and exit interviews
(Wessman et.al, 2001). The sample for the study is 129 EFNEP graduates of average age
of 37 years, all of whom are females, with complete data for dietary recalls, biometric
measures and food practice scores. EFNEP graduates are defined as program participants
who completed all their lessons as well as both the entry and exit interviews (Wessman
et.al, 2001). Participants were recruited during the first EFNEP class, during which they
agreed to allow collection of their biometric measures.
For each individual, the biometric measures collected are, height, weight, body
mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood
sugar level (HbA1C), and pulse rate. These measures were collected with clinical
diagnostic instruments and taken at four different time points: pre (at the first lesson), post
(at the final lesson), and 6 and 12 months after the lesson series. At each time point, the
average of multiple measures was taken for each biometric measure. The participants were
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given cash incentives of $30 (pre), $30 (post), $50 (6 months post), and $50 (12 months
post). (RNECE final report, 2019).
Table 2: Demographic and biometric data from pretest(n=129)
Variable

Mean (sd)

Age (Years)

37.4 (10.7)

Colorado State
Washington State
Height (cm)

159.0(7.5)

Weight (kg)

80.8(20.9)

BMI (kg/m2)

31.9(7.6)

Systolic blood pressure (mmHg)

109.0(12.4)

Diastolic blood pressure (mmHg)

75.6(8.6)

Hemoglobin A1c

5.6(0.9)

Pulse Rate

77.5(24.5)

Number of complete observations
Source: RNECE final report, 2019
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Figure 1 summarizes the pre-EFNEP biometric indicators for the sample of 129 EFNEP
participants. The majority of the sample participants were between the ages of 25 and 40
years. At the first lesson, most of the participants weighed between 60kg and 120kg and
were between 155cm and 175cm tall. Some participants had weight above 120kg with two
out of the five outliers having height above 175cm.
Body Mass Index (BMI) was centered between 20 kg/m2 and 50 kg/m2 with the
Hemoglobin A1C Test (HbA1C) centering between 4mmol/L and 7mmol/L. Normal BMI
range is between 18.5 to 24.9 kg/m2. BMI range greater than 29.9 are considered obese
(Center for Disease Control, 2020). Normal blood sugar levels (HbA1C) ranges below
5.7mmol/L. HbA1C levels greater than 6.5mmol/L are considered diabetic. Participants

Figure 1: Pre-EFNEP demographic and biometric data distribution
with higher systolic blood pressure (SBP) also had high diastolic blood pressure (DBP).
Most of the participants who had SBP between 80mmHg and 130mmHg also had DBP
between 60mmHg and 90mmHg. Normal ranges of SBP and DBP are less than 120mm Hg
and 80mm Hg respectively. There were few participants with DBP greater than 90mmHg.
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The main cost-benefit analysis will be done with the entire data excluding participants with
missing values.
3.2 Data
Both primary and secondary data play an important role in quantifying the
economic benefits of EFNEP. To calculate the direct and indirect benefits of EFNEP,
primary and secondary data were obtained from four sources. Biomarkers were collected
in 2017 and 2018 as part of the long-term follow-up evaluation of EFNEP by the Regional
Nutrition Education and Obesity prevention Centers of Excellence (RNECE). Identical
models of the clinical equipment were used at each time point by trained professionals to
collect the biometric measurements including scales, stadiometers, blood pressure
monitors, and HbA1c test kits.
The goal of the evaluation was to determine if EFNEP impacted participants’
biomarkers (BMI, BP, HbA1c) and if participants of EFNEP could be retained for one year
(RNECE final report, 2019). Demographic characteristics, food and physical activity
questionnaires and 24-hour dietary recalls are administered at entry and at exit to measure
behavior change. This was collected through EFNEP's Web-Based Nutrition Education
Evaluation and Reporting System (WebNEERS). Food Practice Checklist (FPC) questions
were answered by the participants to measure specific food consumption and handling
behaviors on a scale of 1-5.
In addition to biomarker and WebNEERS data, estimates from the literature
(Hradek et. al., 2015) were used to calculate program direct and indirect benefits. These
estimates include average age of onset and years of survival of the diseases, number of
years diseases are delayed as a result of participation in EFNEP, per patient medical costs
discounted to 2020 dollars, average age of retirement, average number of annual lost
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workdays, incidence rate of the disease in the low-income population, incidence rate of the
disease related to diet, incidence rate of disease related to biomarkers and minimum wage
rate. Annual costs of lost workdays were obtained by multiplying the average number of
annual lost workdays, eight hours of daily work hours and the 2020 federal minimum
wage for covered nonexempt employees of $7.25 per hour (US Department of Labor, n.d.).
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Table 3: Data used for calculating direct and indirect benefits

Disease
Condition

Av. age
of
participa
nts

Av. Age of
onset

Av.
Years of
survival

No. of
years
onset
delayed

average
lifespan

Per patient
cost adjusted
to 2020
Dollars

Av. age of
retirement

Annual
Av.
cost of lost
number of
workdays
annual lost
(2020
workdays
dollars)

Type A Diseases
Colorectal
Cancer

37

50

5

5

78

$34,793

65

50

$2,900.00

Heart disease

37

55

5

5

78

$14,830

65

59

$3,422.00

Stroke

37

45

10

5

78

$22,984

65

65

$3,770.00

Hypertension

37

41

20

5

78

$805

65

40

$2,320.00

Type B Diseases
Osteoporosis
Type 2
Diabetes

37

50

78

$10,669

65

7

$406.00

37

54

78

$8,670

65

11

$638.00

Obesity
Foodborne
Illness
Infant
Diseases

37

40

78

$2,046

65

3.72

$215.76

37

24

78

$1,811

65

1.5

$87.00

37

0

78

$2,539

65

$21,799

65

Type C Diseases
Low
Birthweight

37

Source: Hradek et. al., 2015

0

78
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Data on direct costs (Table 4) are also utilized in this study. Direct costs associated
with EFNEP were annual direct costs of adult EFNEP (2018 Dollars) obtained from
collaborators on the pilot project. The direct costs consisted of the value of resources,
including direct payments of real and in-kind dollars, used in program administration and
implementation. They included salaries and benefits; facilities (office space, IT support
and utilities); equipment, supplies and training; staff travel; and marginal excess burden
(17%).
Table 4: Summary of Annual Direct Costs (2018 Dollars) - FTE % Approach
Category
Salaries and Benefits

Cost
$1,221,053.80

Office Space

$124,204.77

Utilities

$13,217.29

Equipment, Supplies and Training

$155,195.62

Staff Travel

$43709.56

Marginal Excess Burden (17%)

$264754.78

Total Direct Cost

$1822,135.82

Source: (Administrative costs assembled from EFNEP Washington and Colorado
Extension)
3.3 The Cost-Benefit Analysis Methodology.
Cost-benefit analysis (CBA) is commonly used to inform society which project or
program to choose from among a number of similar programs. An accurate CBA thus
requires a precise and unbiased definition or identification of benefits and costs that are
generated from the program (Torrance, G.W, 2006). To decide on the desirability of a
project, all positive and negative aspects of the project should be expressed in terms of a
common unit (Watkins and Valley, 2006). The most convenient and most used common
unit is money. This means that all benefits and costs of a project should be measured in
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terms of their equivalent money value of a particular time. The CBA methodology is
applicable for this study as it analyzes a single program to determine whether its benefits
outweigh its cost. The program has economic value if it contributes positively to human
well-being (Frew, E., 2010). The ultimate role of CBA is to aid in allocating scarce
resources.
Results of CBA are usually represented as (1) the discounted net benefit, which is
the difference between program benefits and costs, (2) a ratio of benefits to costs, or (3) a
rate of return (Net Present Value (NPV)/Internal Rate of Return (IRR)) (Boardman et al.
2017). Discounting is a way to compare benefits and costs that occur in different time
periods by expressing their values in present terms since a dollar available five years from
now is not as good as a dollar available now. That dollar can be invested and earn interest
in the next 5 years. For example, if r is the interest rate, then investing $1 now will grow
to be of 1(1 + 𝑟)𝑡 in the next t years. Therefore, the amount of money needed to be
deposited to today so that it will grow to be $1 in the next t years is 1(1 + 𝑟)−𝑡 . 1(1 + 𝑟)−𝑡
is referred to as the present value of $1 which will be available in the future. (1 + 𝑟)𝑡 is
called the discount factor. When applied properly, discounting can inform us about how
much a future benefit or cost of a project or program is worth today (Neubauer et al., 2010).
Thus, when the dollar value of the benefits or costs of a project is multiplied by the
discounted value of $1 at that future time, the result referred to as the discounted present
value (Watkins and Valley, 2006).

CBA provides a framework for measuring the

efficiency of programs and projects and it can be thought of as a method whereby resources
are valued in their highest-valued uses. (Boardman et al. 2017). Such a quantitative
comparison of a program’s benefits to its costs has been widely applied in the evaluation
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of health programs within the United States (Schuster et al, 2006, Hradek et al., 2017). The
cost-benefit ratio is used to ascertain the value of a program by determining whether its
benefits outweigh its costs within a specific period. The ratio gives the value of the
discounted benefits obtained per the costs of the program and is defined as follows:
𝐶𝑜𝑠𝑡 − 𝐵𝑒𝑛𝑓𝑖𝑡 𝑅𝑎𝑡𝑖𝑜(𝐵𝐶𝑅) =

𝑃𝑟𝑒𝑠𝑒𝑛𝑡 𝑉𝑎𝑙𝑢𝑒 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠
𝑃𝑟𝑒𝑠𝑒𝑛𝑡 𝑉𝑎𝑙𝑢𝑒 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑠

𝑇𝑜𝑡𝑎𝑙 𝐵𝑛𝑒𝑓𝑖𝑡𝑡
)
(1 + 𝑟)𝑡
=
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑡
∑𝑛𝑡=1 (
)
(1 + 𝑟)𝑡
∑𝑛𝑡=1 (

(1)

where r is the discount rate which captures the level of future uncertainty and n is the
number of years in the future for discounting.
A potentially worthwhile project is one which has its discounted present value of
the benefits exceeding the discounted present value of the costs. Equivalently, the ratio of
the present value of the benefits to the present value of the costs (cost-benefit ratio) must
be greater than one. A cost-benefit ratio of less than one means that discounted present
value of the costs exceeds the discounted present value of the benefits. A benefit-cost ratio
that is equal to 1 means that there is a break-even situation where the discounted present
value of the benefits of the program equals its discounted present value of costs. When
comparing alternative programs, the program with the highest benefit-cost ratio is
preferred.
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3.4 Monetizing Benefits of EFNEP
Estimated medical costs avoided or delayed for each disease/condition represented
the direct benefits of EFNEP. The assumption is that participants practicing Optimal
Nutritional Behaviors (ONB) and those with biomarker improvement will save these
medical costs by avoiding or delaying the diseases. Benefits such as reduced food costs,
food production and preservation, better use of nutritional food related resources and job
readiness and performance would not be included in the benefit calculations because these
data are not consistently or routinely collected across states in EFNEP and cannot be easily
monetized (Rajgopal et al., 2002).
Medical costs used were 2017 present value medical costs of diseases obtained
from existing literature (Hradek et al., 2017). The future benefits for each disease which
were the costs avoided for some specific time periods were discounted to 2020 dollars at a
discount rate of 5% which is the rate used for most cost benefit analyses (CBAs) in
healthcare studies (Rajgopal et al., 2002). Indirect benefits that accrue to EFNEP
participants are the lost earnings of wages from lost productivity. This indirect benefit
calculation assumes that the individual loses personal wages from lost workdays when he
or she becomes ill from any of these chronic diseases. The 2020 federal minimum wage
for employees of $7.25 per hour were used in calculating the lost earnings from lost
productivity. Chronic diseases and conditions are categorized into three types: Type A,
Type B, and Type C.
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The monetized benefit of avoiding or delaying a disease/condition is the sum of the
present value of direct benefits (medical costs avoided or delayed) and the present value of
indirect benefit (lost earnings of wages from lost productivity forgone), as follows.
Estimated PV Benefits = PV of direct benefit + PV of indirect benefit
𝑛

𝑛

𝑡=1

𝑡=1

𝐷𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
)+ ∑(
)
= ∑(
𝑡
(1 + 𝑟 )
(1 + 𝑟 ) 𝑡

(2)

3.5 Type A Disease Benefits
Type A consists of life-threatening diseases, which are normally incurable, can
considerably reduce a person's life expectancy and are associated with nutritional
behaviors that are expected to be affected positively by appropriate diet behaviors. These
are heart disease, colorectal cancer, hypertension, and stroke. The estimated present value
of total benefit of type A disease consist of direct and indirect benefit of delaying the onset
of the disease:
Est PV benefits of delaying Type A disease =
= PV of Type A direct benefit + PV of Type A indirect benefit
𝑛

𝑛

𝑡=1

𝑡=1

𝑇𝑦𝑝𝑒 𝐴 𝐷𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
𝑇𝑦𝑝𝑒 𝐴 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
= ∑(
) +∑(
)
𝑡
(1 + 𝑟)
(1 + 𝑟)𝑡
(3)
The direct benefits of type A diseases are the present value of medical costs avoided as a
result of delaying the onset of the diseases as a result of participation in EFNEP. For
example, if the average age of onset of a type A disease is at age 50, and EFNEP can delay
the onset for 5 years to age 55, then the estimated present value medical cost avoided for
the 5 years of delay (from age 50 to 54) becomes the benefit of delaying the disease. For
type A diseases, the present value of medical costs is estimated for the average years of
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survival. The direct benefit of type A diseases is calculated as the difference between the
sum of the present value of treatment costs from average age of onset to average age of
death and the sum of the present value of the treatment costs from the delayed age of onset
to the delayed age of death. The present value of all benefits is discounted to 2020 dollars
to determine how much future benefit is worth today.
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =
𝑛

𝑛

𝑡=1

𝑡=1

𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡 𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡
𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡
= ∑(
) − ∑(
)
𝑡
(1 + 𝑟)
(1 + 𝑟)𝑡

(4)

𝑃𝑉 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡𝑠𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 =
𝑛

= ∑(
𝑡=1

𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑎𝑡ℎ
)
( 1 + 𝑟 )𝑡

(5)

𝑃𝑉 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡𝑠𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑑𝑒𝑎𝑡ℎ
= ∑(
)
(1 + 𝑟)𝑡
𝑛

(6)

𝑡=1

Table 5: Type A disease Direct Benefit Illustration:
Present value of Stroke treatment
cost if incurred at age of onset till
death
Age
year
PV
37-44
8
$0.00
45
9
$14,815.42
46
10
$14,109.93
47
11
$13,438.03
48
12
$12,798.12
49
13
$12,188.69
50
14
$11,608.27
51
15
$11,055.50

Present value of stroke
treatment cost if delayed for 5
years
Age
year
PV
37-49
13
$0.00
50
14 $11,608.27
51
15 $11,055.50
52
16 $10,529.04
53
17 $10,027.66
54
18 $9,550.15
55
19 $9,095.38
56
20 $8,662.27
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52
53
54
Total

16
17
18

$10,529.04
$10,027.66
$9,550.15
$120,120.81

57
58
59
Total

21
22
23

$8,249.78
$7,856.94
$7,482.80
$94,117.80

PV of Direct Benefit of delaying Stroke = $120,120.81 - $94,117.80 = $26,003.01
Type A disease indirect benefits are the loss of productivity avoided due to the
delay of the onset of the diseases. The loss of productivity prevents the individual from
earning wages. Therefore, the benefits from avoiding the loss of productivity are the wages
that would have been forgone. The indirect benefit of type A diseases is the difference
between the sum of the present values of lost wages from the average age of onset to
average age of death and the sum of the present value of lost wages from the delayed age
of onset to the delayed age of death – discounted to 2020 dollars.
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝐷𝑖𝑠𝑒𝑎𝑠𝑒 𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝐸𝑛𝑒𝑓𝑖𝑡 =
𝑛

𝑛

𝑡=1

𝑡=1

𝐿𝑜𝑠𝑡 𝑤𝑎𝑔𝑒𝑠𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡
𝐿𝑜𝑠𝑡 𝑊𝑎𝑔𝑒𝑠𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡
) −∑(
)
= ∑(
𝑡
(1 + 𝑟 )
(1 + 𝑟 )𝑡

(7)

𝑃𝑉 𝑜𝑓 𝐿𝑜𝑠𝑡 𝑊𝑎𝑔𝑒𝑠𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝑙𝑜𝑠𝑡 𝑜𝑓 𝑤𝑎𝑔𝑒𝑠 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑑𝑒𝑎𝑡ℎ
= ∑(
)
(1 + 𝑟)𝑡
𝑛

(8)

𝑡=1

𝑃𝑉 𝑜𝑓 𝐿𝑜𝑠𝑡 𝑊𝑎𝑔𝑒𝑠𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝑙𝑜𝑠𝑡 𝑜𝑓 𝑤𝑎𝑔𝑒𝑠 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑑𝑒𝑎𝑡ℎ
= ∑(
)
(1 + 𝑟)𝑡
𝑛

𝑡=1

(9)
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Table 6: Type A Disease Indirect Benefit Illustration:
Present value of lost wages from
stroke if incurred at average age of
onset
Age
year
PV
37-44
8
$0.00
45
9
$2,430.18
46
10
$2,314.45
47
11
$2,204.24
48
12
$2,099.28
49
13
$1,999.31
50
14
$1,904.11
51
15
$1,813.43
52
16
$1,727.08
53
17
$1,644.84
54
18
$1,566.51
Total
$19,703.43

Present value of lost wages
from stroke if delayed for 5
years
Age
year
PV
37-49
13
$0.00
50
14
$1,904.11
51
15
$1,813.43
52
16
$1,727.08
53
17
$1,644.84
54
18
$1,566.51
55
19
$1,491.92
56
20
$1,420.87
57
21
$1,353.21
58
22
$1,288.77
59
23
$1,227.40
Total
$15,438.15

Indirect Benefit of Stroke Disease = $19,703.43 - $15,438.15 = $4,265.277
3.6 Type B Diseases Benefits
Type B disease and conditions are non-life-threatening diseases, which are diseases
that can be treated and are also associated with nutritional behaviors that are affected
positively by appropriate diet behaviors. These are obesity, type 2 diabetes, osteoporosis,
foodborne illness, and commonly occurring infant diseases. The estimated present value of
total benefit of type B disease consist of direct and indirect benefit of delaying the onset of
the disease.
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Est PV benefits of delaying Type B disease =
= PV of Type B direct benefit + PV of Type B indirect benefit
𝑛

𝑛

𝑡=1

𝑡=1

𝑇𝑦𝑝𝑒 𝐵 𝐷𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
𝑇𝑦𝑝𝑒 𝐵 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑡
= ∑(
+
∑
)
(
)
(1 + 𝑟)𝑡
(1 + 𝑟)𝑡
(10)
The benefits of type B diseases are the estimated present value of medical costs
avoided as a result of avoiding the onset of the disease through the rest of one’s lifetime
until the average life expectancy by participating in the program. For example, if the life
expectancy is at age 78, and the average age of onset of the disease is at age 50, then the
present value of medical costs one could have incurred from age 50 till average lifespan is
the benefit of avoiding the disease.
For type B diseases, the present value of medical costs is estimated for the average
lifespan of the individual from the onset of the disease. The direct benefit of type A diseases
is calculated as the sum of the present value of treatment costs from average age of delayed
age of onset through the rest of the lifetime (average age of death), discounted to 2020
dollars. The present value of all benefits is discounted to 2020 dollars.
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑎𝑡ℎ.
= ∑(
)
(1 + 𝑟 )𝑡
𝑛

𝑡=1

(11)
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Table 7: Type B Disease Direct Benefit Illustration
Present value of Type 2 Diabetes treatment costs if avoided
for the rest of lifetime.
Age
year
PV
37-53
18
$0.00
54
19
$3,431.21
55
20
$3,267.82
56
21
$3,112.20
57
22
$2,964.00
58
23
$2,822.86
59
24
$2,688.44
60
25
$2,560.42
61
26
$2,438.49
62
27
$2,322.38
63
28
$2,211.79
64
29
$2,106.46
65
30
$2,006.15
66
31
$1,910.62
67
32
$1,819.64
68
33
$1,732.99
69
34
$1,650.47
70
35
$1,571.87
71
36
$1,497.02
72
37
$1,425.74
73
38
$1,357.84
74
39
$1,293.19
75
40
$1,231.61
76
41
$1,172.96
77
42
$1,117.10
78
43
$1,063.91
Total PV
$50,777.19
Direct Benefit for Type 2 Diabetes = $50,777.19

Type B disease indirect benefits are the loss of productivity avoided due to avoiding
the diseases until the age of retirement. The loss of productivity prevents the individual
from earning wages therefore the benefits from avoiding the loss of productivity are the
wages that would have been forgone when one is sick as a result of the disease. The indirect
benefit of type B disease is the sum of the present values of lost wages from average age
of onset to average age of retirement, discounted to 2020 dollars.
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𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝐿𝑜𝑠𝑡 𝑤𝑎𝑔𝑒𝑠 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑜𝑛𝑠𝑒𝑡 𝑡𝑜 𝑑𝑒𝑎𝑡ℎ.
= ∑(
)
(1 + 𝑟)𝑡
𝑛

(12)

𝑡=1

Table 8: Type B Disease Indirect Benefit Illustration
Present value of lost earnings for Type 2 Diabetes until retirement
Age
Year
PV
37-53
18
$0.00
54
19
$252.48
55
20
$240.46
56
21
$229.01
57
22
$218.10
58
23
$207.71
59
24
$197.82
60
25
$188.40
61
26
$179.43
62
27
$170.89
63
28
$162.75
64
29
$155.00
65
30
$147.62
Total PV
$2,349.67
Indirect benefit for Type 2 Diabetes = $2,349.67

3.7 Type C Disease Benefits.
Type C diseases and conditions are those whose cost of treatment is incurred once
only when the child is born such as low birth weight (LBW) in infants. The direct benefit
of Type C diseases and conditions is based on the present value of avoiding the one-time
treatment costs of treating an infant with LBW.

3.8 Cost-Benefit Analysis (CBA) Models
Two different CBA are implemented in this study – the standard CBA model
(Virginia methodology) which measures program benefits using self-reported dietary
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recalls and the biomarker CBA model which uses biomarkers for benefit estimation.
Previous CBA studies on EFNEP have employed the use of the standard model (Lambur
et al. 1998, Radhika et al. 2002., and Hradek, et al., 2017) but the use of biomarkers is quite
uncommon in the field of nutrition education. The use of the clinically measured and
objective biometric data will help to eliminate bias and error such as under-reporting and
over-reporting associated with the use of self-reported data. The difference in the
methodologies is that while the total benefit estimation of the standard Virginia method
uses graduates practicing ONB (calculated from the self-reported behavioral data) and the
incidence rate of the disease related to diet, the biomarker method calculates the number
of graduates with biomarker improvement and uses the risk of disease related to the
biomarker in estimation of the benefits.
3.9 Standard CBA Model.
Following the literature, I first apply the Virginia methodology utilized in prior
CBA of EFNEP (Lambur et al. 1999, Radhika et al. 2002, & Burney et al., 2002). The
Virginia methodology uses self-reported behavioral data to determine the participants who
are delaying or avoiding the diseases as well as uses the incidence rate of diseases related
to diet to quantify the total benefits of the program. To avoid or delay the onset of the
diseases, the participants must meet the selection criteria (recommended dietary behavior
guidelines) in Table 6 (Wessman et al., 2001). The standard methodology estimates total
benefit as the product of the total number of graduates in the program, the incidence rate
of the disease in low-income population, incidence rate of the disease related to diet, the
percent of graduates achieving optimal nutrition behavior and the present value of

32

estimated benefit of avoiding or delaying the disease. The benefits for each disease are
calculated using the formula:
𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 = 𝑁 × 𝐼𝑙 × 𝐼𝑑 × 𝑔𝑟𝑎𝑑𝑂𝑁𝐵 × 𝑃𝑉(𝑏𝑒𝑛𝑒𝑓𝑖𝑡)

(13)

Where N is the total number of EFNEP graduates, Il is the incidence rate of disease in Lowincome population, Id is incidence rate of disease related to diet, gradONB is the percentage
of graduates achieving optimal nutrition behaviors (ONB) conditions for the specific
disease, and PV(benefit) is the present value of the estimated benefit of avoiding or
delaying the disease. The standard model calculates the total benefit of participating in
EFNEP as the sum of benefits for each disease.
𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑚𝑜𝑑𝑒𝑙 = ∑ 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒

(14)

3.10 Incidence Rate of the Disease/Condition
The incidence rates which measure the probability of occurrence of the diseases in
a low-income US population within a specified period of time are provided in Table 5.
These were obtained from a recent CBA of Iowa EFNEP (Hradek et.al, 2017). When
possible, incidence rates specifically for the low-income US population are utilized. Where
rates for the low-income population cannot be found, the incidence rates for the general
population are used. The incidence rates of the diseases related to diet measure the portion
of the occurrence of the disease/condition believed to be related to diet over a specific
period. The rates act as a proxy for the percentage of EFNEP graduates who would
normally get a disease or condition, but who might avoid or delay its onset by adopting
recommended nutrition behaviors (Wessman et.al, 2001).
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Table 9: Incidence Rates of Disease Related to Diet in the Low-Income Population.
Disease/condition

Incidence rate of the

Incidence rate of the

disease in the low-income

disease related to diet

population
Colon Cancer

8.0%

80%

Heart Disease

25.8%

50%

Stroke

8.1%

49%

Hypertension

29.3%

45%

Osteoporosis

10.3%

15%

Diabetes

28.0%

45%

Obesity

38.0%

50%

Foodborne Illness

16.7%

100%

Infant Diseases

100.0%

22%

8.0%

100%

Low Birthweight (LBW)
Source: Hradek et.al (2017).

3.11 Selecting Graduates Practicing Optimal Nutritional Behaviors (ONB)
STATA statistical software was used to select participants among the 129 sample
graduates who practiced optimal nutrition behaviors (ONB) at exit and those who had
improvement in their biomarkers at exit, 6 months after graduation and 1 year after
graduation. To be selected as practicing ONB, the participant must meet the selection
criteria for ONB (see Table 5 in the Table 10). Graduates who were missing critical data
related to the ONB were eliminated from the selection. The standard CBA model uses
optimal nutritional behaviors (ONB) in Table 6 to determine whether a graduate avoids or
delays the onset of a chronic disease or condition. The ONB criteria for a specific
disease/condition were applied to entry and exit 24-hour food recall and the Food Practice
Checklist (FPC) questions which measure food consumption behaviors and food handling
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practices on a scale from 1 to 5. To be considered as a graduate practicing ONB, the
graduate must satisfy the criteria at graduation, but not at entry. This is because satisfying
the criteria at entry implies that the participant was already practicing ONB and that
EFNEP did not impact his or her behavior (Lambur, et al., 2015).
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Table 10 : Optimal Nutrition Behavior Criteria By Disease (Based on 2015-2020 DGA)
Disease

Normal Graduates
(2000 kcal)

Colon Cancer

total fat ≤ 78gms,
saturated fat ≤ 22gms
fiber ≥ 25gms,
fv ≥ 4.5cup-eq
total fat ≤ 78gms,
saturated fat ≤ 22gms
fiber >= 25gms,
fv>= 4.5cup-eq
Fv ≥ 4.5 cup-eq,
Ca ≥ 1000mg
Ca ≥ 1,000 mg ,
Dairy ≥ 3 cup-eq
fiber ≥ 25gms,
kcal ≤ 2300 kcal
carbohydrate ≤ 325gms

Heart Disease

Stroke/Hypertension
Osteoporosis
Diabetes

Obesity

fiber ≥ 25gms,
fv ≥ 4.5cup-eq
total fat ≤ 78gms,
saturated fat ≤ 22 gms
kcal ≤ 2300 kcal

Pregnant or Nursing
graduates
(2600 kcal)
total fat ≤ 101,
saturated fat ≤ 29gms
fiber ≥ 28gms,
fv ≥ 5cup-eq
total fat ≤ 101,
saturated fat ≤ 29gms
fiber ≥ 28gms,
fv ≥ 5cup-eq
Fv ≥ 5 cup-eq,
Ca ≥ 1000mg
Ca ≥ 1,000 mg ,
Dairy ≥ 3 cup-eq
fiber ≥ 28gms,
kcal ≤ 2600 kcal for
pregnant women
kcal ≤ 2500 kcal for
nursing women
carbohydrate ≥ 423gms
fiber ≥ 28gms,
fv ≥ 5cup-eq
total fat ≤ 101,
saturated fat ≤ 29gms
kcal ≤ 2600 kcal for
pregnant women
kcal ≤ 2500 kcal for
nursing women

FPC(questions #)

FPC score

7&9

≥4

8&9

≥4

8&9

≥4

7

≥4

7&9

≥4

7&9

≥4
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Foodborne Illness
Infant Diseases
Low Birthweight

yes for nursing

yes for pregnant
kcal>=2200

The Optimal Nutrition Behavior (ONB) Criteria is based on 2015-2020 Dietary Guidelines.
FPC # Q5. This question is about meat and dairy foods. How often do you let these foods sit out for more than two hours?
Q6. How often do you thaw frozen foods at room temperature?
Q7. When deciding what to feed your family, how often do you think about healthy food choices?
Q8. How often have you prepared foods without adding salt?
Q9. How often do you use the “Nutrition Facts” on the food label to make food choices?

Source (Hradek et al., 2017)

Table 11 : Percent of Graduates Practicing Optimal Nutrition Behaviors
Disease

Graduates practicing ONB
entry - exit

Colon Cancer

7.5%

Heart Disease

7.5%

Stroke
Hypertension
Osteoporosis
Type 2 Diabetes
Obesity
Foodborne Illness
Infant Diseases
Low Birth Weight

12.5%
12.5%
5%
12.5%
5%
19.23%
27.5%
-

5&6
7
9

≤2
≥4
≥4
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3.12 Biomarker CBA Model
There are obvious limitations to self-reporting in that some people may not
remember food intake and exercise levels correctly, or they may have difficulty quantifying
them accurately (Combs et al., 2013). This problem may lead to underestimation or
overestimation of the results when self-reported data are used in the analysis (Park et al.,
2018). To solve the problem of using self-reported data in the standard model, biomarkers,
which are objective and quantitative biological measurements that indicates the potential
for developing a disease or medical condition in an individual are used. In this model, the
assumption is that behaviors learnt from EFNEP impact chronic disease biomarkers i.e.
BMI, blood pressure and HbA1C. A participant’s improvement in the biomarkers provides
a means to accurately measure the benefits of EFNEP. Biomarkers provide almost unbiased
measurements and are therefore useful to validate self-report instruments (Hagen, 2012).
The biomarker model also uses the PV of medical cost and lost earnings of avoiding the
diseases (Type A, B and C) as the benefits. The difference between the two models is that
while the standard CBA model uses graduates achieving ONB conditions for each disease
and the incidence rate of disease related to diet, the biomarker model uses instead, the
number of graduates improving their biomarkers and the risk of the disease related to the
biomarker respectively. The benefit of each disease calculated using the biomarker model
is:
𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 = 𝑁 × 𝐼𝑙 × 𝐼𝑏 × 𝑔𝑟𝑎𝑑𝑖𝑚𝑏𝑟𝑜𝑣𝑒 𝑏𝑖𝑜 × 𝑃𝑉(𝑏𝑒𝑛𝑒𝑓𝑖𝑡)

(15)

where N is the total number of EFNEP graduates, Il is the incidence rate of disease in the
low-income population, Ib is incidence rate of disease related to biomarker, gradimprove bio
is the percentage of graduates improving in their biomarkers for the specific disease, and
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PV(benefit) is the present value of the estimated benefit of avoiding or delaying the
disease. The biomarker model calculates the total benefit of participating in EFNEP as the
sum of benefits for each disease.
𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟 𝑚𝑜𝑑𝑒𝑙 = ∑ 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒

(16)

The risk of the disease related to the biomarkers is used as a measure of the portion of the
occurrence of the disease/condition related to changes in the biomarker over a specific
period. These rates give an indication of the likelihood of developing or having the
disease/condition as a result of changes in biomarkers.
3.13 Identification of EFNEP Graduates with Biomarker Improvement
The goal of EFNEP is ultimately to improve the nutritional health of participants,
therefore it follows that, by practicing these behaviors, biological characteristics such as
weight, blood sugar, blood pressure, etc., which are indicators of good health and proper
nutrition behaviors will be impacted. The criteria for determining graduates with biomarker
improvement were based on general population rates of standard status categories of
biomarkers provided by the Center for Disease Control (CDC) and the American Heart
Association (provided in Table 12). The criteria for selecting graduates who have
improvement in biomarkers are presented in Table 13. To be selected as having
improvement in biomarkers at graduation, there must be quantitative change in values of
biomarkers towards the normal category of each biomarker. For example, using the normal
BMI range as a reference point, an overweight or obese graduate is selected to have
improvement in BMI when BMI at graduation (exit) is less than the BMI at entry, and an
underweight graduate is selected as having improvement in BMI when the BMI at
graduation (exit) is greater than the BMI at entry. The same criteria were used to determine
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graduates who had improvements in their biomarkers six months after graduation and one
year after graduation. Graduates who were missing critical data related to biomarkers were
eliminated from the sample. The risks of diseases associated with the biomarkers are
presented in Table 10. Figure 2 provides the percentage of graduates who had
improvements in their biomarkers at graduation (entry-exit), 6 months after graduation
(entry-6months) and 1 year after graduation (entry-1year).
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Table 12: Biomarker Status Categories.
Biomarker Range (general
population)
Less than 18.5
BMI

18.5 to 24.9
25.0 to 29.9
Systolic: less than 120
mm Hg

Category

Source

Underweight
Normal/Healthy
weight range
Overweight

Center for Disease Control
(2020)

Normal

SBP &
DBP

Pulse

Blood
Sugar

Diastolic: less than 80
mm Hg
Systolic: 120-129 mm
Hg

Center for Disease Control
(2020)

Elevated
Diastolic: less than 80
mm Hg
Systolic: 130 mm Hg
or higher
Diastolic: 80 mm Hg
or higher
78 - 157

Below 5.7%
5.7% to 6.4%
6.5 or above %

High Blood
Pressure
(hypertension)
Target heart rate American Heart Association
zone (50-85%)
Guidelines for the
prevention, detection,
evaluation, and Management
of high blood pressure in
adults (2017)
Normal
Center for Disease Control
Prediabetes
(2020)
Diabetes

Table 13: Criteria for Selecting Graduates Who Had Biomarker Improvement
Biomarker

Direction of Improvement

Criteria for determining improvement in
biomarkers at graduation
entry BMI is less than 18.5 &

Underweight to Normal

exit BMI greater than entry BMI &
exit BMI < 24.9

BMI
Overweight and Obese to

entry BMI > 24.9 &

normal

exit BMI < entry BMI &
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exit BMI >18.5
SBP

Elevated and high BP to

entry SBP > 129 &

normal

exit SBP < entry SBP

DBP

High BP to Normal

Pulse

Changes towards the target
heart rate zone

HbA1C

Changes from prediabetic
and diabetic towards
normal

entry DBP > 80 &
exit DBP < entry DBP
entry Pulse < 78 &
exit Pulse > entry Pulse &
exit Pulse < 132
entry HbA1C > 5.7 &
exit HbA1C < entry HbA1C

Table 14: Risk of Chronic Disease Associated with Changes in Biomarkers
Disease/condition

Biomarker used

Risk of disease
associated to
biomarker

Source

Type A Diseases
Heart Disease

BMI

21%

WHO, 2009

Hypertension

Blood pressure

12%

Harvard SPH, 2020

Colorectal Cancer

BMI

30%

Harvard SPH, 2020

Stroke

Pulse

23%

WHO, 2009

HbA1C

66%

Harvard SPH, 2020

BMI

100%

Harvard SPH, 2020

Osteoporosis1

48%

Hradek et.al (2017).

Foodborne illness1

100%

Hradek et.al (2017).

22%

Hradek et.al (2017).

Type B Diseases
Type 2 diabetes
Obesity

Type C diseases
Infant diseases1
1.

There was no direct relationship between biomarkers and osteoporosis, foodborne illness and infant
diseases based on existing literature, therefore the risk of the disease associated to diet was used.

42

Figure 2: Percentage of graduates having improvement in biomarker
BMI and pulse rate had the highest percentage of graduates improving their biomarkers for
all the three periods. There was an improvement in the percentage of graduates who had
improved BMI, but there was not much change from 6 month to 1 year post-EFNEP . SBP
had the lowest percent of graduate improving at all time periods (15.4%, 11.5%, 13.5%).
DBP had the highest percentage of improvement at 1 year after graduation. The percentage
of graduates improving in their blood sugar (HbA1C) was highest at exit (30.8%) and
lowest after one year of graduation (17.3%). There were lower percent of graduates with
improvement for pulse at 1 year after graduation (44.2%) compared to the higher percent
of graduates with improvement of at graduation (51.9%) and at 6 months after graduation
(53.8%).
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CHAPTER 4
4.1 Results
The final sample size used in the analysis is 129 EFNEP graduates with complete
data. Table 11 below provides the number and percentages of graduates who practiced
ONB at exit of the program, as well as graduates who improved their biomarkers for the
diseases at exit, 6 months post and one year post. For all the diseases except foodborne
illness and infant diseases, the percentage of graduates with improved biomarkers exceeded
the percentage with improved ONB across all three periods: graduation, six months after
graduation and one year after graduation. No graduates were selected for practicing ONB
or improving biomarkers for low-birth-weight disease. This is because there were no
pregnant participants in the study sample. The highest percentage of graduates practicing
ONB at exit is 27.5% for avoiding infant diseases and the lowest percentage of graduates
practicing ONB at exit is 5% for avoiding obesity. The highest percentage of graduates
improving their biomarkers are 51.92% for avoiding stroke at exit, 53.85% for avoiding
stroke at 6 months after graduation and 50% for avoiding colon cancer, heart disease, and
obesity after one year of graduation.
Table 15: Percentage of Graduates Improving in Their Biomarkers for Each Disease
Number & percentage of graduates avoiding disease
Graduates practicing
ONB
entry - exit

entry-exit

entry-6months

entry-1yr

Colon Cancer

7.5%

42.31%

50.0%

50.0%

Heart Disease

7.5%

42.31%

50.0%

50.0%

Stroke

12.5%

51.92%

53.85%

44.23%

Hypertension

12.5%

30.77%

25.00%

132.69%

Osteoporosis

5%

72.20%

72.20%

72.20%

Disease

Graduates improving in biomarkers
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Type 2 Diabetes

12.5%

30.77%

19.23%

17.31%

Obesity

5%

42.31%

50.0%

50.0%

Foodborne Illness

19.23%

19.23%

19.23%

19.23%

Infant Diseases

27.5%

9.62%

9.62%

9.62%

Low Birth Weight

-

-

-

-

A summary of the CBA results calculated using the cost-benefit ratio formula in
equation (1) for both models is provided in Table 12. The PV of total benefit is derived by
the summation of the total direct benefit and the total indirect benefit which is then
compared to the total costs. The total cost of the program ($1,822,135.82) was obtained by
adding the total administrative costs from the Washington and Colorado EFNEP programs.
The cost-benefit ratio is derived by dividing the total benefit by the total cost. From
Table 12, the estimated PV of total direct benefits, which are the medical costs avoided or
delayed, obtained by using the biomarkers at graduation ($15,695,056.81), six months after
graduation ($15,610,152.67), and one year after graduation ($15,150,042.08) are higher
than the estimated PV of total direct benefit ($4,383,751.24) obtained at graduation when
dietary recalls (self-reported data) are used.
The PV of total indirect benefits (lost productivity/wages avoided or delayed)
obtained using the biomarkers at graduation ($1,375,117.55), six months after graduation
($1,444,849.32), and one year after graduation ($1,420,879.22) is much higher than the
estimates of PV of total indirect benefits obtained at graduation from using the self-reported
data ($361,939.46). The estimated PVs of direct, indirect and total benefits calculated from
the standard model, using self-reported data, are lower than the estimated PVs of direct,
indirect and total benefits calculated using the biomarker model. The PV of total benefits
from the standard model is $4,745,690.69 compared to the much higher PV of total benefit
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of $17,070,174.36, $17,055,002.00, and $16,570,921.30 for all the three time periods using
the biomarker model. Benefits were compared to the costs and incorporated into a benefitcost ratio. From the standard model, EFNEP generates a benefit-cost ratio of $2.60: $1.00.
The biomarker model yields benefit-cost ratios of $9.37: $1.00, $9.36: $1.00, and $9.09:
$1.00 at exit, six months post and 1 year post respectively.
Table 16: Cost-Benefit Analysis Results
Standard model

Biomarker model

entry - exit

entry - exit

entry - 6 month

entry – 1 year

$4,383,751.24

$15,695,056.81

$15,610,152.67

$15,150,042.08

$361,939.46

$1,375,117.55

$1,444,849.32

$1,420,879.22

Total benefits

$4,745,690.69

$17,070,174.36

$17,055,002.00

$16,570,921.30

Total costs

$1,822,135.82

$1,822,135.82

$1,822,135.82

$1,822,135.82

$2.60: $1.00

$9.37: $1.00

$9.36: $1.00

$9.09: $1.00

Total direct benefits
Total indirect benefits

Cost-benefit ratio

4.2 Sensitivity Analysis
Healthcare evaluations are prone to the uncertainties that beset the methodologies,
assumptions and data which have implications on the interval of the estimates (Briggs and
Gray, 1999). Sensitivity analysis is therefore important to evaluate the robustness of the
assumptions in CBA. This is to determine how the uncertainties in the models and the data
impact the estimated CBA results, and hence determine the range or confidence of the
estimates (Sendi, Garfni and Birch, 2002).
The 5% discount rate, which describes the level of uncertainty in the time value of
money, is commonly used in health- related studies (Attema et al., 2018). Since there is
some uncertainty about using this value, a sensitivity analysis is done by varying the
discount rate (0%, 3%, 7% and 10%). The incidence rates of the infant disease and
foodborne illness related to diet were used in the biomarker models since there were no
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studies found in the literature that provided an association of biomarkers to those diseases,
so it is important to conduct a sensitivity analysis on these rates in the biomarker model. A
sensitivity analysis is performed by reducing the incidence rates of infant disease and
foodborne illness used in the biomarker model by 50%.
Table 17: One Way Sensitivity Analysis Table
Standard
Model

BCR
interval

Biomarker Model

Entry – Exit

Entry – Exit

Entry 6months

Entry – 1year

0% discount rate

$6.57

$24.54

$22.65

$21.99

3% discount rate

$3.60

$13.22

$12.83

$12.47

7% discount rate

$1.98

$6.94

$7.10

$6.89

10% discount rate

$1.42

$4.71

$4.95

$4.80

50% reduction of
incidence rates of infant
diseases and foodborne
illness

$2.60

$8.89

$8.88

$8.61

Sensitivity interval

($1.42 $6.57)

($4.71 $24.54)

($4.95 $22.65)

($4.80 $21.99)

($6.57 $22.65)
($3.60 $13.22)
($1.98 $7.10)
($1.42 $4.95)
($2.6 $8.89)

The results indicate that the CBA outcome remained positive after altering the
parameters. However, the benefit-cost ratio changed significantly for each analysis. The
findings from the sensitivity analysis are consistent with that of the primary results of the
cost-benefit analysis. The results were more sensitive to the varying the discount rate than
to reducing the incidence rates for foodborne and infant diseases. Assuming no uncertainty
in the model (0% discount rate) had the greatest impact on the benefit-cost ratios for both
models. The cost-benefit ratio of the biomarker model lies within the sensitivity interval of
$4.71 - $24.54: $1.00 for all the three time periods. The cost-benefit ratio of the standard
model lies within the sensitivity interval of $1.42 - $6.57:$1.00. The sensitivity analysis
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leads to the same conclusion that estimates from the biomarker model are higher than
estimates from the standard model.
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CHAPTER 5
5.1 Discussion and Recommendation
The cost-benefit ratios presented in Table 12 indicate that EFNEP generates
significant return on investment. These results corroborate the positive returns found in
prior EFNEP studies (Rajgopal et al., 2002; Lambur et al., 2009 and Hradek et al., 2017).
The standard model, which uses self-reported dietary recall data from EFNEP participants,
indicates a $2.67 return on every $1.00 invested (sensitivity: $1.42 - $6.57). The result
from the standard model possesses measurement errors due to the use of self-reported
dietary recalls. Therefore, to address the problems associated with the use of self-reported
data, objective and clinically measured biomarkers of participants collected at graduation,
6 months after graduation and 1 year after graduation are used to estimate the benefits of
EFNEP.
The results from using the biomarkers indicate an average return of $9.27 on every
$1.00 invested (sensitivity: $4.71 - $24.54). The significant difference in the results from
the two models emphasizes the bias, measurement errors, and underestimation associated
with the use of self-report data (Rosenman et al., 2011). The use of biomarkers for chronic
disease risk provides more accurate results that better reflect the true benefit of EFNEP.
The results from both models indicate that taxpayer dollars are used effectively in
addressing the issue of nutrition insecurity among low-income families. As individuals
learn and implement proper nutritional behaviors and can avoid or delay the onset of these
diseases by participating in the program, they are able to save these medical costs which
may be used in purchasing food and other necessities for their families. The benefit-cost
ratios from the biomarker model for all the three periods are approximately $9.00 for each
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period which suggests that the nutritional behaviors derived from the EFNEP program are
maintained for at least 1 year after participants graduate from the program.
Results from this study suggest that the program provides an effective use of
taxpayer dollars in addressing nutrition insecurity. EFNEP participants experience
sustained improvement in nutritional health through the adoption and maintenance of the
behaviors taught in the program, and in wellbeing by avoiding or delaying specific
disease/conditions. The results off this study can be used by EFNEP coordinators to
demonstrate to policymakers the positive value of the program as well as leverage the
information to increase the amount of funding available in support of this program obtained
from a limited pool of state and federal dollars. Consequently, additional funding to be
allocated to the program will allow to increase the impact of nutrition education
disseminated to low-income families and youth in the 50 states, the U.S. territories, and the
District of Columbia.
The results of this study show how using biomarkers could provide more accurate
estimates of the true benefits of EFNEP. Nonetheless, this is a preliminary study with a
small sample size. Therefore, additional studies will be needed using a large nationally
representative dataset to ascertain and make firm generalizations of the results from this
study. To effectively evaluate the benefits of EFNEP, we suggest that self-reported dietary
recalls should be supplemented with biological markers (biomarkers) which are objective
and reflective of nutritional intake to estimate the benefits of the program. Considering the
additional cost of collecting these biomarkers from EFNEP participants, we recommend
that the biometric data should be collected in some interval years based on decision by
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EFNEP coordinators. For example, biometric data from EFNEP participants could be
collected once every 5 years to determine whether EFNEP remain worthwhile.

5.2 Limitations of study
A key limitation of this study is the large share of participants with missing data on
dietary recalls and biomarkers. About 50% of the total sample had to be dropped due to
incomplete data. Because I compare graduates practicing ONB to those improving in
biomarkers, I ensured that observations in the data had complete values for both dietary
recalls, biomarkers, and food practice scores, but this led to a significant reduction in the
sample size. Other data issues were the unavailability of more representative data on the
incidence rates of disease related to biomarkers and the data on the costs of collecting
biometric data from participants. Since EFNEP participants are low-income earners and
are mostly women, rates of diseases related to biomarkers for low-income earners or
women would have provided more accurate and representative results than using general
population rates. Also, to determine the direct costs of collecting the biometric data from
participants, it will require additional cash incentives for the volunteers, the cost of labor
for collecting the data and the cost of medical supplies such as scale, stadiometer, blood
pressure machine, blood sugar test kits, etc.
An important factor to consider, in assessing the impacts on graduates who
benefited from the program at graduation, are the individuals’ underlying medical
conditions. This information could have been inferred from the data with the observations
that were potential outliers. Nonetheless it will be difficult to determine if participants had
underlying medical conditions, such as stroke, cancer, etc. Knowing this information could
provide additional beneficial information in estimating the benefits.
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The percentage of EFNEP graduates improving each biomarker were estimated as the as
the percentage of EFNEP graduates who had quantitative improvement in biomarkers (e.g.
an obese participant having a reduction in BMI at exit) regardless of the magnitude of
improvement. Another approach is to consider participants who made qualitative
improvement, or those who had categorical movement e.g., obese to normal weight. Both
approaches have their own limitations. Regardless of the magnitude of the difference in
biomarker values at entry and exit, moderate improvement is clinically significant as an
improvement in health (Kirk et al., 2005 and Lemstra et al., 2016). Categorical changes of
these biomarkers will require a longer duration outside that of the program to occur,
therefore, this is expected to occur when these behaviors are maintained long-term.
The biometric data for blood sugar (HbA1C) were collected one time for each
participant. Even though this is objective and more accurate than self-reported data, this
could have potential measurement errors since the level of blood sugar can be highly
influenced by other factors, such as the kind of food taken in a particular day, the day’s
activity, etc. A more accurate measure of blood sugar levels could have been the weighted
average of multiple measures collected.
5.3 Future Research
Biomarkers, which are indicators of nutrient intake, status, or functional effects are
needed to support evidence-based clinical guidance and effective health programs and
policies related to food, nutrition, and health (McClure 2002). Studies by Pico et al. ( 2019),
and McClure (2002) and others have established the impact of nutritional behavior on the
biomarkers of individuals. Since diet behavior impacts biomarkers, it will be useful to
develop a model or define a relationship that links changes in diet to improvement in
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biomarkers. Such a model could be used to estimate or predict biometric changes of EFNEP
participants given their dietary recalls so that, costs incurred in collecting biometric data
from participants to evaluate EFNEP in the future could be avoided in the future. For more
accurate results, this would need to be done using biometric and dietary recall data from a
large, nationally representative sample of EFNEP participants.
Another important question to ask about the impact of EFNEP is how the behaviors
learnt from the program impact the biomarkers of participants. Since it was assumed in the
biomarker model that EFNEP impacts biomarkers, it is important to determine if the
changes in the biomarkers at graduation, 6 months and 1 year after graduation were caused
by EFNEP or if these changes occurred randomly. Statistical tests, such as paired sample
tests and ANOVA, will be important in determining the statistical significance of the effect
of the program on these biomarkers. The results from this study will provide another means
of evaluating the programs impact and further guide EFNEP program coordinators
programmatic decisions.
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